CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌的肿瘤微环境及其 CAR-T 细胞免疫治疗靶向策略
英文原题：The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
查看英文原题
The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是肝癌的主要亚型，其发病率在癌症中居第六位，死亡率居第三位。尽管在HCC的新型治疗方面取得了巨大进展，例如免疫治疗，但预后仍不尽如人意。越来越多的证据表明，肿瘤免疫微环境（TME）在HCC的演变中发挥重要作用，并对HCC治疗疗效具有不可忽视的影响。在过去二十年中，利用嵌合抗原受体修饰T（CAR-T）细胞疗法在血液系统恶性肿瘤中取得的成功使其在癌症治疗中具有巨大前景。然而，面对HCC等实体瘤中不利的TME，CAR-T 细胞的疗效将大打折扣。在此，我们概述HCC中TME的特征，讨论CAR-T 免疫治疗在HCC中的最新进展和挑战。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is the major subtype of liver cancer, which ranks sixth in cancer incidence and third in mortality. Although great strides have been made in novel therapy for HCC, such as immunotherapy, the prognosis remains less than satisfactory.
Increasing evidence demonstrates that the tumor immune microenvironment (TME) exerts a significant role in the evolution of HCC and has a non-negligible impact on the efficacy of HCC treatment. In the past two decades, the success in hematological malignancies made by chimeric antigen receptor-modified T (CAR-T) cell therapy leveraging it holds great promise for cancer treatment.
However, in the face of a hostile TME in solid tumors like HCC, the efficacy of CAR-T cells will be greatly compromised.
Here, we provide an overview of TME features in HCC, discuss recent advances and challenges of CAR-T immunotherapy in HCC.
论文信息
- 作者
- Guizhen Z、Guanchang J、Liwen L、Huifen W、Zhigang R、Ranran S、Zujiang Y
- 单位
- Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in endocrinology2022
- 原文标识
- PubMed 36093115 · DOI 10.3389/fendo.2022.918869
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →